ANTERIS TECHNOLOGIES LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23 AUD | -1.67% |
|
-2.34% | +20.10% |
| Apr. 18 | Anteris Technologies Posts AU$10.6 Million Cash, AU$20.2 Million Net Cash Outflows for Quarter Ended March 31 | MT |
| Apr. 10 | Anteris Technologies Raises AU$23 Million for DurAVR Study | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Anteris Technologies Ltd is an Australia-based company that is engaged in the research and development (R&D) of its structural heart products. The Company is engaged in the manufacture and sale of ADAPT regenerative tissue products globally. It is focused on developing biomimetic transcatheter aortic valve replacement (TAVR) for the treatment of aortic stenosis. ADAPT is the Companyâs patented anti-calcification tissue technology. Its DurAVR THV is a three dimensional (3D) single piece valve and is a biomimetic design that replicates the normal blood flow of a healthy human aortic valve. The Company also provides ComASUR Delivery System, a balloon expandable system with the ability to rotate valves for predictable alignment with the heartâs native commissure.
Calendar
2024-05-28
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
23.39
AUD
Average target price
30
AUD
Spread / Average Target
+28.26%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +20.10% | 289M | |
| -4.36% | 183B | |
| -3.87% | 105B | |
| -4.38% | 67.36B | |
| +8.23% | 51.77B | |
| +15.54% | 47.29B | |
| -1.73% | 40.2B | |
| +7.16% | 27.62B | |
| -17.29% | 21.75B | |
| -1.68% | 25.51B |
- Stock Market
- Equities
- AVR Stock
- News Anteris Technologies Ltd
- Anteris Technologies Implants Five TAVR Patients with DurAVR Valve in Aortic Stenosis Study; Shares Surge 18%
